Ankylosing spondylitis of multiple sites in spine
Methodology & AI Transparency ⓘ
Ankylosing spondylitis of multiple sites in spine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Ankylosing spondylitis of multiple sites in spine—coded clinically as M45.0 across Autoimmune Disease guidelines—combines early treat-to-target disease-modifying in Ankylosing spondylitis of multiple sites in spine (M45.0: antirheumatic (DMARD/biologic) therapy) with structured follow-up of hs-CRP & ESR [Ankylosing spondylitis of multiple sites in spine M45.0] (hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M45.0)).
- 2 Real-world patient consensus: Diagnostic registry M45.0: Ankylosing spondylitis of multiple sites in spine is managed within Autoimmune Disease.
- 3 Typical cash cost range: Workup highlights for Ankylosing spondylitis of multiple sites in spine (M45.0): early treat-to-target disease-modifying in Ankylosing spondylitis of multiple sites in spine (M45.0: antirheumatic (DMARD/biologic) therapy).
- 4 Top reported side effects / signs: Key Autoimmune Disease biomarkers for Ankylosing spondylitis of multiple sites in spine (M45.0): CBC, ALT & in Ankylosing spondylitis of multiple sites in spine (M45.0: Creatinine (DMARD safety)) & hs-CRP & ESR [Ankylosing spondylitis of multiple sites in spine M45.0] (hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M45.0)).
Ask our AI Specialists anything about Ankylosing spondylitis of multiple sites in spine
What Is Ankylosing spondylitis of multiple sites in spine?
Ankylosing spondylitis of multiple sites in spine—coded clinically as M45.0 across Autoimmune Disease guidelines—combines early treat-to-target disease-modifying in Ankylosing spondylitis of multiple sites in spine (M45.0: antirheumatic (DMARD/biologic) therapy) with structured follow-up of hs-CRP & ESR [Ankylosing spondylitis of multiple sites in spine M45.0] (hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M45.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Ankylosing spondylitis of multiple sites in spine (M45.0, Autoimmune Disease) reflects vascular inflammation [Ankylosing spondylitis of multiple sites in spine M45.0]. longitudinal control is benchmarked via CBC, ALT & in Ankylosing spondylitis of multiple sites in spine (M45.0: Creatinine (DMARD safety)).
Common Symptoms & Clinical Signs
- • Presentation of Ankylosing spondylitis of multiple sites in spine (M45.0): symmetric swelling and in Ankylosing spondylitis of multiple sites in spine (M45.0: warmth in small)
- • Secondary Ankylosing spondylitis of multiple sites in spine clinical sign: systemic inflammatory fatigue, in Ankylosing spondylitis of multiple sites in spine (M45.0: low-grade fevers, dry)
- • Symptom flares in Ankylosing spondylitis of multiple sites in spine correlating with CBC, ALT & in Ankylosing spondylitis of multiple sites in spine (M45.0: Creatinine (DMARD safety)) deviation outside Within normal safety monitoring limits (M45.0)
- • Functional autoimmune disease impact requiring early treat-to-target disease-modifying in Ankylosing spondylitis of multiple sites in spine (M45.0: antirheumatic (DMARD/biologic) therapy) evaluation (M45.0)
Ankylosing spondylitis of multiple sites in spine Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M45.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Rheumatoid Arthritis, Lupus & Autoimmune | NLM Clinical Tables |
| Diagnostic / Lab Marker: CBC, ALT & in Ankylosing spondylitis of multiple sites in spine (M45.0: Creatinine (DMARD safety)) | Within normal safety monitoring limits (M45.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & ESR [Ankylosing spondylitis of multiple sites in spine M45.0] | hs-CRP < 1.0 mg/L; ESR < 15 mm/hr (M45.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ANA, RF, Anti-CCP in Ankylosing spondylitis of multiple sites in spine (M45.0: & Complement C3/C4) | Disease-activity remission targets (M45.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ankylosing spondylitis of multiple sites in spine
Treatment selection for Ankylosing spondylitis of multiple sites in spine depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ankylosing spondylitis of multiple sites in spine)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of baricitinib in patients with systemic lupus erythematosus: an: What a 1,655-Participant Study Found The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. RMD open • 2023-08-15 • Phase III Randomized Trial | N = 1,655 | 96/100 | PMID 37604638 ↗ |
| New Insights on Validation of the Ankylosing Spondylitis Quality of Life assessment tool in: What a 325-Participant Study Found Our findings suggest that the ASQoL is an appropriate outcome measure in interventional clinical trials in patients with nr-axSpA. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation • 2021-03-15 • Phase III Randomized Trial | N = 325 | 93/100 | PMID 33128725 ↗ |
| New Insights on Benefits and safety of Tofacitinib in Ankylosing Spondylitis by Baseline: What a 372-Participant Study Found Regardless of baseline CRP, TOF was more efficacious vs placebo at week 12. The Journal of rheumatology • 2024-08-01 • Phase III Randomized Trial | N = 372 | 93/100 | PMID 38825359 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Intravenous Golimumab in Ankylosing Spondylitis Patients Prompt diagnosis of AS and early treatment with IV golimumab may yield more robust improvements in disease activity. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases • 2022-08-01 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 35653615 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparative assessment of how the body absorbs the medicine parameters between The systemic exposure of HS016 was similar to that of adalimumab in healthy subjects and AS patients, demonstrating PK similarity. Advances in clinical and experimental medicine : official organ Wroclaw Medical University • 2022-05-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35148573 ↗ |
Ankylosing spondylitis of multiple sites in spine Patient Community & “People Like Me” Threads
Filter Ankylosing spondylitis of multiple sites in spine community threads and patient logs by age, biological sex, dosage, and treatment duration.